WALL STREET JOURNAL | A group of 20+ pharmaceutical companies have created a $1-billion fund to address the growing antibiotic-resistance crisis by supporting the development of up to four new new antibiotics by 2030. David Ricks, Chairman and CEO of Eli Lilly, and Kasim Kutay, CEO of Novo Holdings, underscore the important work that CARB-X and other organizations have done to revitalize the early-stage pipeline. But these efforts face a lack of investors willing to shoulder the high costs and risks of later stages of development. The AMR Action Fund will shoulder some risk and expense, at least for a few years. But it is not a permanent solution. It is time for policy makers and government to take the bold actions needed to prevent another pandemic.